Immunogenicity, Efficacy and Safety of Treatment With Human-cl-rhFVIII in Previously Untreated Patients With Severe Hemophilia A
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Simoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Pharmacodynamics; Registrational
- Acronyms NuProtect
- Sponsors Octapharma
- 10 Jul 2017 Interim results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress.
- 19 Apr 2017 Interim results presented at the Hemostasis and Thrombosis Research Society Scientific Symposium 2017, according to an Octapharma USA media release.
- 19 Apr 2017 Interim results (n=66) published in an Octapharma USA media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History